Non-Fucosylated Anti-Human CD19 (MDX-1342) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-645ZP) Datasheet

Target
CD19
Isotype
Human IgG
Description
ADCC-Enhanced anti-CD19 (MDX-1342) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform. By reducing the fucosylation of the Fc region, the ADCC-enhanced antibody shows an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Chronic Lymphocytic Leukemia; Rheumatoid Arthritis
Classification
Therapeutic antibody; biobetter
Status
Phase 1

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 molecule
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Gene ID
930
Cellular Localization
Plasma membrane
HGNC
1633
Ensembl
ENSG00000177455
OMIM
107265
Involvement in Disease
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Related Pathways
Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).
Function
As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signal pathway activation and trigger b-cell response to antigen. Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage. Not needed in the early steps of bone marrow B cell differentiation. Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges. Requires normal levels of serum immunoglobulin, and the production of high-affinity antibodies upon antigen challenge.
Field of research
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Post-translational modifications
Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Phosphorylated on tyrosine residues by LYN.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human IgG
Antibody Clone
MDX-1342
Host
Human
Species Reactivity
Human
Description
MDX-1342 is a fully human monoclonal antibody (HuMAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function, targeting CD19-membrane receptor which is highly expressed on malignant chronic lymphocytic leukemia (CLL) cells.
Indication
Chronic Lymphocytic Leukemia; Rheumatoid Arthritis

Chronic Lymphocytic Leukemia; Rheumatoid Arthritis

Related Products

ADCC-Enhanced Anti-Human CD19 (Tafasitamab) Antibody, a biobetter (CAT#: BioBet-CB-003LX)
Highly Galactosylated Anti-CD19 Taplitumomab paptox, a Biobetter Antibody (CAT#: BioBet-GA-103ZP)
Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1674ZP)
Non-Fucosylated Anti-Human CD19 (R005-1) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1694ZP)
Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1794ZP)
Highly Galactosylated Anti-CD19 Blinatumomab, a Biobetter Antibody (CAT#: BioBet-GA-010ZP)
Non-Fucosylated Anti-Human CD19 (4G7) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1693ZP)
Highly Galactosylated Anti-CD19 Taplitumomab, a Biobetter Antibody (CAT#: BioBet-GA-100ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK